Table 1.
EBMT Population Characteristics
| Derivation cohort 2014–2016 | Tuning cohort 2012–2013 | Geographic Validation cohort~ 2014–2016 | |
|---|---|---|---|
| N | 25,534 | 18,365 | 3,366 |
| Age, years (median [IQR]) | 53 [41, 62] | 51 [39, 60] | 52 [40, 60] |
| Sex (%) | |||
| Male | 15,019 (58·8%) | 10,842 (59·0%) | 1,911 (56·8%) |
| Female | 10,459 (41·0%) | 7,488 (40·8%) | 1,453 (43·2%) |
| Sex unknown | 56 (0·2%) | 35 (0·2%) | 2 (0·1%) |
| Karnofsky Performance Status | |||
| ≥ 90 | 17, 465 (68·4%) | 13,139 (71·5%) | 2,585 (76·8%) |
| < 90 | 6,172 (24·2%) | 4,017 (21·9%) | 741 (22·0%) |
| Unknown | 1,897 (7·4%) | 1,209 (6·6%) | 40 (1·2%) |
| Diagnosis (%) | |||
| Aggressive Lymphoma* | 1,457 (5·7%) | 1,062 (5·8%) | 211 (6·3%) |
| Acute Lymphoblastic Leukemi^ | 3,474 (13·6%) | 2,699 (14·7%) | 561 (16·7%) |
| Acute Myeloid Leukemia | 11,881 (46·5%) | 8,248 (44·9%) | 1,578 (46·9%) |
| Chronic Lymphocytic Leukemia | 564 (2·2%) | 768 (4·2%) | 54 (1·6%) |
| Hodgkin’s Disease | 741 (2·9%) | 599 (3·3%) | 189 (5·6%) |
| Indolent Lymphoma ¶ | 827 (3·2%) | 751 (4·1%) | 98 (2·9%) |
| Multiple Myeloma | 852 (3·3%) | 783 (4·3%) | 90 (2·7%) |
| Myelodysplastic Syndrome | 2,977 (11·7%) | 1,700 (9·3%) | 303 (9·0%) |
| Myeloproliferative Neoplasms$ | 2,761 (10·8%) | 1,755 (9·6%) | 282 (8·4%) |
| Cell source (%) | |||
| Bone marrow | 2,126 (8·3%) | 2,261 (12·3%) | 1,128 (33·5%) |
| Peripheral blood | 22,943 (89·9%) | 15,514 (84·5%) | 2,198 (65·3%) |
| Cord blood | 465 (1·8%) | 590 (3·2%) | 40 (1·2%) |
| Donor (%) | |||
| Matched related | 8,492 (33·3%) | 6,718 (36·6%) | 979 (29·1%) |
| Haploidentical relative | 1,762 (6·9%) | 989 (5·4%) | 897 (26·6%) |
| Matched unrelated (10/10) | 7,689 (30·1%) | 5,679 (30·9%) | 747 (22·2%) |
| Mismatched unrelated (< 10/10) | 2,071 (8·1%) | 1,988 (10·8%) | 446 (13·3%) |
| Unknown match unrelated | 5,055 (19·8%) | 2,401 (13·1%) | 257 (7·6%) |
| Unrelated cord blood | 465 (1·8%) | 590 (3·2%) | 40 (1·2%) |
| Sex-match (%) | |||
| Not female-to-male | 20,432 (80·0%) | 14,359 (78·2%) | 2,577 (76·6%) |
| Female-to-male | 4,565 (17·9%) | 3,586 (19·5%) | 707 (21·0%) |
| Unknown sex-match | 537 (2·1%) | 420 (2·3%) | 82 (2·4%) |
| CMV serostatus pair (%) | |||
| Donor − / Recipient − | 6,777 (26·5%) | 4,408 (24·0%) | 346 (10·3%) |
| Donor − / Recipient + | 5,330 (20·9%) | 4,234 (23·1%) | 843 (25·0%) |
| Donor + / Recipient − | 2,098 (8·2%) | 1,537 (8·4%) | 233 (6·9%) |
| Donor + / Recipient + | 10,289 (40·3%) | 7,421 (40·4%) | 1,782 (52·9%) |
| CMV unknown | 1,040 (4·1%) | 765 (4·2%) | 162 (4·8%) |
| Conditioning intensity (%) | |||
| Myeloablative | 12,476 (48·9%) | 9,964 (54·3%) | 2,494 (74·1%) |
| Reduced-intensity | 12,400 (48·6%) | 8,050 (43·8%) | 856 (25·4%) |
| Unknown | 658 (2·6%) | 351 (1·9%) | 16 (0·5%) |
~
Italian centers
*
Includes B-cell and T-cell non-Hodgkins’ lymphomas
^
Includes patients with biphenotypic acute leukaemia
¶
Includes patients with mantle cell lymphoma
$
Includes patients with MDS/MPN Overlap
IQR – interquartile range; CMV – cytomegalovirus